Chronic Kidney Disease (CKD) Screening and Management Mobile Apps

Webpage to access the web-based, Apple App Store, and Google Play versions of the Clinician CKD Screening app and the patient-centered Kidney Choices app. IPRO’s Clinician CKD Screening and Patient-Centered Kidney Choices apps were designed to:
-Help identify CKD early in at-risk patients and to help manage CKD
-To help delay progression
-To provide kidney replacement information for patients whose CKD has progressed to kidney failure.

Management of Anticoagulation in the Peri-Procedural Period (MAPPP) app

Webpage for the MAPPP app. Provides links to web-based, Apple App Store and Google Play versions of MAPPP app along with multiple patient education resources directly related to peri-procedural anticoagulant interruption. Surgery and invasive medical interventions increase the risk of bleeding, while withholding anticoagulants increases the risk of thrombosis due to the underlying condition(s) for which anticoagulation was originally prescribed. The clinical team must therefore balance these competing risks and make educated decisions regarding the decision to interrupt oral anticoagulation for a medical procedure and, if interrupted, whether to “bridge” anticoagulation with injectable anticoagulants, such as low molecular weight heparin (LMWH) in warfarin treated patients.

This guide is intended to:

Assist clinicians in the simultaneous evaluation of procedure-related bleeding risk and underlying risk of thrombosis
Guide decisions regarding the interruption of anticoagulation and the use of anticoagulant “bridging”
Provide detailed guidance for drug dosing and laboratory monitoring in the peri-procedural period
Encourage clear communication between clinicians involved in prescribing anticoagulants and performing invasive procedures

National Action Plan for ADE Prevention

The National Action Plan for Adverse Drug Event Prevention (ADE Action Plan) was established to address two key objectives: (1) identify common, preventable, and measurable adverse drug events (ADEs) that may result in significant patient harm; and (2) align the efforts of Federal health agencies to reduce patient harms from these specific ADEs nationally.

On the basis of national ADE data from inpatient and outpatient settings, three types of ADEs were considered to be common, clinically significant, preventable, and measurable, and were therefore selected as the high-priority targets of the ADE Action Plan.
The three initial targets of the ADE Action Plan are:
1. Anticoagulants (primary ADE of concern: bleeding)
2. Diabetes agents (primary ADE of concern: hypoglycemia)
3. Opioids (primary ADE of concern: accidental overdoses/over sedation /respiratory depression)


The ADE Action Plan suggests a four-pronged approach to reduce patient harms from these three ADEs: Surveillance, Prevention, Incentives and Oversight, and Research.

Lessons Learned from the Pandemic that Inform the New Normal: Presentation Recording (12/9/2021)

During this presentation, Dr David Gifford addressed the following:
• Infection Control Practices and immunizations work when widely
used and done consistently
• Staff care deeply about their residents
• Staffing in our sector is a challenge
• Care needs of our residents and emergencies (e.g., hurricanes)
continue despite pandemic
• We have to rely on each other as outside help is often limited

Lessons Learned from the Pandemic that Inform the New Normal: Presentation slides (12/9/2021)

During this presentation, Dr. David Gifford addressed the following:
• Infection Control Practices and immunizations work when widely
used and done consistently
• Staff care deeply about their residents
• Staffing in our sector is a challenge
• Care needs of our residents and emergencies (e.g., hurricanes)
continue despite pandemic
• We have to rely on each other as outside help is often limited

Oral Dosage Forms That Should Not Be Crushed

The Institute for Safe Medication Practices List of Oral Dosage Forms That Should Not Be Crushed, commonly referred to as the “Do Not Crush” list, contains medications that should not be crushed because of their special pharmaceutical formulations or characteristics, such as oral dosage forms that are sustained-release in nature.

Opioid and Pain Management Best Practices: Strategies for Success: Presentation slides (9/22/2021)

This event featured the authors of an initiative, recently published in the American Journal of Addiction. The initiative increased naloxone availability for patients with opioid prescriptions within their health system.

Additionally, we hosted a nursing home consultant pharmacist, who shared processes for implementing a medication-assisted therapy program for opioid use disorder in nursing homes.

Opioid and Pain Management Best Practices: Strategies for Success: Webinar Recording (9/22/2021)

This event featured the authors of an initiative, recently published in the American Journal of Addiction. The initiative increased naloxone availability for patients with opioid prescriptions within their health system.

Additionally, we hosted a nursing home consultant pharmacist, who shared processes for implementing a medication-assisted therapy program for opioid use disorder in nursing homes.